Simufilam found safe in review of ongoing Alzheimer’s clinical trials
WEB5 days ago · by Andrea Lobo September 26, 2024. After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing the oral therapy simufilam in people with Alzheimer’s disease. The board’s findings were announced by ...
Cassava Sciences Announces Completion of an Interim Safety …
WEBSep 24, 2024 · Today’s news follows interim safety MRI data announced in October 2023, which suggests simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities (ARIA).
Cassava Sciences Announces Completion of an Interim Safety
WEBSep 24, 2024 · Today’s news follows interim safety MRI data announced in October 2023, which suggests simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities (ARIA).
Cassava Sciences Announces Completion of an Interim Safety
WEBSep 24, 2024 · Today’s news follows interim safety MRI data announced in October 2023, which suggests simufilam is not associated with treatment-emergent amyloid-related imaging abnormalities (ARIA).
Topline results of Phase 3 studies of simufilam for Alzheimer's...
WEBFeb 8, 2024 · Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.
Simufilam aids cognition in 47% of Alzheimer's patients in Phase 2...
WEBMar 14, 2023 · Nearly half of some 200 mild-to-moderate Alzheimer’s patients treated with oral simufilam for one year showed gains in cognitive tests.
Cassava Sciences Completes Enrollment for Pivotal Phase 3 …
WEBAUSTIN, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate the safety and efficacy of oral simufilam versus placebo in Alzheimer's disease dementia.
Cassava Sciences Announces Positive Top-Line Clinical Results in …
WEBJan 24, 2023 · Simufilam is Cassava Sciences’ proprietary, small molecule (oral) drug candidate that restores the normal shape and function of altered filamin A (FLNA) protein in the brain.
Cassava Sciences Announces Science Publication That Confirms …
WEBSep 11, 2023 · Simufilam is Cassava Sciences’ proprietary, small molecule (oral) drug candidate for the treatment of Alzheimer’s disease dementia. Unlike monoclonal antibody treatments for Alzheimer’s disease, simufilam does not purport to directly remove amyloid β from the brain.
Scientists Investigating Alzheimer’s Drug Faulted in Leaked Report
WEBOct. 14, 2023. A neuroscientist whose studies undergird an experimental Alzheimer’s drug was “reckless” in his failure to keep or provide original data, an offense that “amounts to significant...